Abstract:BACKGROUNDGlioblastoma multiforme (GBM) is an aggressively malignant brain tumor known for its high recurrence rates and dismal survival outcomes. Despite advancements in surgical and therapeutic strategies, the prognosis for GBM patients remains poor. This study applies proteomic analysis to postoperative GBM tumor specimens to identify molecular markers that could enhance prognosis prediction. Through the analysis of protein expression profiles before and after tumor recurrence, we identified significant alterations in protein pathways via Gene Set Enrichment Analysis (GSEA), highlighting potential biomarkers for disease outcome prediction. METHODSWe employed Sequential Window Acquisition of All Theoretical Fragment Ion Spectra (SWATH-MS) proteomics to analyze protein samples from both primary and recurrent GBM patients. Gene Set Enrichment Analysis (GSEA) was utilized to compare protein expression profiles and discern significantly altered pathways. RESULTSAnalysis revealed 778 differentially expressed proteins (DEPs), with notable alterations in pathways such as glycolysis, interleukin signaling, and MAPK signaling. Proteins such as TOLLIP, ENO1, and ITGA2B emerged as potential prognostic markers. Validation through an online tumor prognostic analysis platform (ToPP), integrated with The Cancer Genome Atlas (TCGA) data, facilitated the development of a prognostic risk score model. This model effectively categorized patients into high and low-risk groups based on their protein expression profiles, enhancing the prediction of patient outcomes. The proteins and pathways identified offer new insights into the molecular dynamics of GBM postoperatively. The association between protein expression profiles and patient prognosis underscores the potential of these markers in developing customized therapeutic strategies. Additionally, the prognostic risk score model serves as a valuable tool for improving prognostic accuracy and could guide personalized treatment plans. CONCLUSIONProteomic profiling of GBM tumors significantly contributes to uncovering the molecular mechanisms driving this aggressive cancer and facilitates the development of dependable prognostic tools. These findings not only affirm the critical role of proteomics in cancer research but also advance personalized medicine strategies in GBM management.

Identification of SAA1 As a Prognostic Biomarker Associated with Immune Infiltration in Glioblastoma

SAA1 Expression as a Potential Prognostic Marker of the Tumor Microenvironment in Glioblastoma

SAA1 Knockdown Promotes the Apoptosis of Glioblastoma Cells Via Downregulation of AKT Signaling.

Identification of Novel Human Glioblastoma-Specific Transcripts by Serial Analysis of Gene Expression Data Mining

Clinical significance and potential mechanism of AEBP1 in glioblastoma

AEBP1 as a potential immune-related prognostic biomarker in glioblastoma: a bioinformatic analyses

Identification of Novel Transcriptome Signature as a Potential Prognostic Biomarker for Anti-Angiogenic Therapy in Glioblastoma Multiforme

SAA1 Has Potential as a Prognostic Biomarker Correlated with Cell Proliferation, Migration, and an Indicator for Immune Infiltration of Tumor Microenvironment in Clear Cell Renal Cell Carcinoma

Identification of potential biomarkers and candidate small molecule drugs in glioblastoma

Cnsc-08. Prognostic Biomarker Discovery Through Proteomic Analysis Of Glioblastoma Multiforme

S100A9, as a potential predictor of prognosis and immunotherapy response for GBM, promotes the malignant progression of GBM cells and migration of M2 macrophages

COL8A1 is a potential prognostic biomarker associated with migration, proliferation, and tumor microenvironment in glioma

Comprehensive Gene Set Enrichment and Variation Analyses Identify SUV39H1 As a Potential Prognostic Biomarker for Glioblastoma Immunorelevance

Identification of novel prognostic targets in glioblastoma using bioinformatics analysis

Gene Expression Profiling of Glioblastoma to Recognize Potential Biomarker Candidates

Identification of Key Candidate Genes and Pathways in Glioblastoma by Integrated Bioinformatical Analysis

Identification of a Potential Prognostic Signature based on Immune-related Genes in Primary Glioblastoma

Comprehensive Analysis of CD163 As a Prognostic Biomarker and Associated with Immune Infiltration in Glioblastoma Multiforme.

Identification of angiogenesis‐related genes signature for predicting survival and its regulatory network in glioblastoma

SRSF1 induces glioma progression and has a potential diagnostic application in grading primary glioma

Bioinformatics Analysis of High-Throughput Data to Validate Potential Novel Biomarkers and Small Molecule Drugs for Glioblastoma Multiforme